Neuroscience

#AbbVie #Major depressive disorder #Mergers and acquisitions #Psychedelics #Psychiatry

AbbVie acquires psychedelic for major depressive disorder

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion.  Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and… Read More

#Business & Investment #News

Immunotherapy
#Autoimmune disease #Immunic Therapeutics #Immunology #MS #Neurodegenerative disorders #Neurology

Moving beyond managing autoimmune diseases to progression

What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics’ recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More

#Exclusive Content

#Digital biomarkers #Monument Therapeutics #National Institutes of Health (NIH) #Neuroscience #Schizophrenia

Monument Therapeutics partners on novel treatment for schizophrenia

Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial.  Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis, referred to as… Read More

#Business & Investment #News

Neurons in Parkinson's disease
#Neuroinflammation #Neuroscience #NodThera #Parkinson's #Phase II trial

Oral NLRP3 inhibitor reverses neuroinflammation in Parkinson’s

NodThera has shared positive data from its Parkinson’s disease Phase Ib/IIa study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3 inflammasome inhibitor.  In the first publication to demonstrate the clinical potential of an oral, fully brain-penetrant NLRP3 inhibitor in Parkinson’s disease, NT-0796 was shown to be… Read More

#News

Neuroscience
#Collaboration #JAK inhibitor #Neuroinflammation #Parkinson's #Receptor.AI #Sareum Holdings

Sareum and ReceptorAI collaborate on TYK2/JAK1 inhibitors

Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.  The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s… Read More

#Business & Investment #News

Neurons
#Alzheimer's #Neurodegenerative disorders #Neuroscience #Porosome Therapeutics

New Alzheimer’s therapy restores neurotransmission

Porosome Therapeutics has shared key advancements in its disease-modifying neurological platform, which it claims will transform Alzheimer’s Disease (AD) research and treatment by offering a new approach that goes beyond symptom management.   The company has demonstrated a relatively rapid reduction of the Alzheimer’s pathology in AD human… Read More

#News

Human brain
#Mergers and acquisitions #Neurodegenerative disorders #Neuroscience #Sanofi #Vigil Neuroscience

Sanofi completes acquisition of Vigil Neuroscience

Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.  Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.  Sanofi will also acquire Vigil’s preclinical pipeline… Read More

#Business & Investment #News

Human brain
#Drug discovery #Multiple sclerosis #Neurodegenerative disorders #Neuroscience

Does EBV trigger multiple sclerosis and drive its progression?

Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties. For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral… Read More

#Exclusive Content

Proteomics
#Alzheimer's #Collaboration #Nautilus Biotechnology #Neuroscience #Partnership #Proteomics

Nautilus forms partnership to better understand Alzheimer’s

Proteome analysis company Nautilus Biotechnology has announced a partnership with the Allen Institute focused on improving our understanding of neurodegenerative conditions.  The organisations will investigate the connection between the tau protein and its occurrence in neurodegenerative conditions such as Alzheimer’s disease.  Recent studies suggested that… Read More

#Business & Investment #News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 4 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there… Read More

#News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neuroscience

This week in drug discovery (28 July – 1 August) 

News round-up for 28 July – 1 August by DDW Senior Digital Content Editor Diana Turner. With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there have been a number of updates in the neuroscience drug discovery field. The top stories:… Read More

#News

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

#AltPep Corporation #Alzheimer's #Neuroscience #Peptides

Peptide for Alzheimer’s increases clearance of amyloid plaques

AltPep Corporation has presented new preclinical data on its lead compound, Soluble Oligomer Binding Inhibitor (SOBIN-AD), as a treatment for early Alzheimer’s disease (AD) at the Alzheimer’s Association International Conference (AAIC).   The preclinical data show SOBIN-AD:  Binds amyloid beta (Aβ) oligomers 27,000-fold stronger than… Read More

#News

#Financing #Funding #MapLight Therapeutics #Neuroscience

MapLight Therapeutics makes $372.5m in series D financing

MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing.   The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T Rowe Price Investment Management, Inc. and Avego BioScience Capital.  … Read More

#Business & Investment #News

Drugs targeting amyloid Plaque
#Alzheimer's #Neuroscience #Phase III trial #Roche

Roche’s AD study shows rapid clearance of amyloid plaques

Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.  Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle Alzheimer’s disease (AD) study and design of the Phase III TRONTIER 1 and 2… Read More

#Editor's Choice #News

Neurons
#Amyotrophic lateral sclerosis (ALS) #Biogen #MHRA #MND #Neuroscience

First new ALS treatment approved in UK in 30 years

Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).  The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tofersen through the International… Read More

#News #Regulatory #Trending News